| Bioactivity | GSK-3β inhibitor 7 is a GSK-3β inhibitor with an IC50 value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder[1]. |
| Invitro | GSK-3β inhibitor 7 (Compound 6x, 5 μΜ, 3 h) shows high glucose uptake (83.5%) in musle L6 cells[1].GSK-3β inhibitor 7 (0-30 μΜ, 30 min) inhibits GSK-3β with an IC50 value of 5.25 μM[1]. |
| In Vivo | GSK-3β inhibitor 7 (Compound 6x, oral administration, 20 mg/kg) shows favorable drug-like properties (t1/2: 5.4 h, Cmax: 507 ng/mL) and oral bioavailability in rats[1].GSK-3β inhibitor 7 (intragastric administration, 1 g/kg) displays no acute toxicity at a 1 g/kg dose in mice[1]. Animal Model: |
| Name | GSK-3β inhibitor 7 |
| Formula | C27H23BrN4O2S |
| Molar Mass | 547.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shuwen Han, et al. Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues. Bioorg Chem. 2022 Feb;119:105537. |